未经批准：如今，目前尚无针对COVID-19的有效治疗方法,早期识别和支持治疗对于降低COVID-19的发病率和死亡率至关重要.这是第一项评估D-二聚体与淋巴细胞比率（DLR）作为COVID-19患者预后效用的研究。
UNASSIGNED：我们回顾性分析了611例患者，并将其分为幸存者和非幸存者组。使用受试者工作特征（ROC）曲线比较了纳入COVID-19预后的各种预测因子的曲线下面积（AUC）。为了确定DLR与COVID-19患者生存率之间的相互作用，选择Kaplan-Meier(KM)曲线。
未经评估：年龄（OR=1.053；95％CI，1.022-1.086；P=0.001），NLR（OR=1.045；95%CI，1.001-1.091；P=0.046），CRP(OR=1.010;95%CI,1.005-1.016;P<0.001),PT（OR=1.184；95%CI，1.018-1.377；P=0.029），DLR(OR=1.048;95%CI,1.018~1.078,P=0.001)是影响COVID-19死亡的独立危险因素。DLR对COVID-19死亡率的预测价值最高，AUC为0.924。与DLR较低的患者相比，患者的生存率较低（LogRankP<0.001）。
未经证实：DLR可能是COVID-19患者死亡的危险因素。
Nowadays, there is still no effective treatment developed for COVID-19, and early identification and supportive therapies are essential in reducing the morbidity and mortality of COVID-19. This is the first study to evaluate D-dimer to lymphocyte ratio (DLR) as a prognostic utility in patients with COVID-19.
We retrospectively analyzed 611 patients and separated them into groups of survivors and non-survivors. The area under the curve (AUC) of various predictors integrated into the prognosis of COVID-19 was compared using the receiver operating characteristic (ROC) curve. In order to ascertain the interaction between DLR and survival in COVID-19 patients, the Kaplan-Meier (KM) curve was chosen.
Age (OR = 1.053; 95% CI, 1.022-1.086; P = 0.001), NLR (OR = 1.045; 95% CI, 1.001-1.091; P = 0.046), CRP (OR = 1.010; 95% CI, 1.005-1.016; P < 0.001), PT (OR = 1.184; 95% CI, 1.018-1.377; P = 0.029), and DLR (OR = 1.048; 95% CI, 1.018-1.078; P = 0.001) were the independent risk factors related with the mortality of COVID-19. DLR had the highest predictive value for COVID-19 mortality with the AUC of 0.924. Patients\' survival was lower when compared to those with lower DLR (Log Rank P <0.001).
DLR might indicate a risk factor in the mortality of patients with COVID-19.
PDF(Pubmed)